Treatment patterns and outcomes in patients with metastatic synovial sarcoma in France, Germany, Italy, Spain and the United Kingdom Supplementary Material
Funding
This study was funded by GSK (212253). N Patel is an employee of GSK, a former employee of Merck, and owns stocks/shares in GSK. S Pokras is an employee of GSK and owns stocks/shares in GSK. J Ferma, V Casey and F Manuguid are employees of IQVIA Inc, which has received funding from GSK. K Culver was an employee of GSK at the time of the manuscript submission, and is a former employee of Novartis, and owns stocks/shares in GSK. S Bauer has received honoraria from Bayer, Deciphera, GSK, Novartis, Pfizer and PharmaMar; was in a consulting or advisory role for ADC Therapeutics, Adcendo, Bayer, Blueprint Medicines, Boehringer Ingelheim, Daiichi Sankyo, Deciphera, Exelixis, GSK, Janssen-Cilag, Lilly, Mundipharma and Nanobiotix; has received research funding from BlueprintMedicines, Incyte (institution received funding) and Novartis; and has received travel, accommodations or expenses from PharmaMar. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Editorial support was provided by F Wignall, of Fishawack Indicia, part of Fishawack Health, and T Taylor of Scion (London, UK), and writing support was provided by E Giannakouri of Scion, and was funded by GSK.
